Caladrius Biosciences, Inc. (CLBS) Social Stream

Featured Post From StockTwits About CLBS

$CLBS IN CASE YOU FORGOT?
CLBS Stock Price Increases Over 130%

By Amit Chowdhry ● January 20, 2021 -(6 months ago)

The stock price of Caladrius Biosciences Inc. is trading up more than 130% pre-market today.

KEY QUOTES:
“We are extremely excited about our CLBS16 program. It represents a breakthrough in the treatment of CMD. Currently there are no products with approved labeling for coronary microvascular dysfunction.
— David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Hospital Health Network in Cincinnati, Ohio.

The 105-patient double-blind and placebo-controlled clinical trial was designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells (CLBS16) in subjects with CMD and without obstructive coronary artery disease.

When a diagnosis of CMD is missed, patients are untreated and remain at elevated risk of heart risk or cardiovascular-related death.
Caladrius’ CLBS16 program has demonstrated great promise.